form-20200328
False0001039399December 262020Q1222222277,017273,0010.0010.00110,000,00010,000,000————0.0010.001250,000,000250,000,00076,158,25175,764,99076,158,25175,764,990nono111100010393992019-12-292020-03-28xbrli:shares00010393992020-05-04iso4217:USD00010393992020-03-2800010393992019-12-28iso4217:USDxbrli:shares00010393992018-12-302019-03-300001039399us-gaap:CommonStockMember2019-12-280001039399us-gaap:AdditionalPaidInCapitalMember2019-12-280001039399us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-280001039399us-gaap:RetainedEarningsMember2019-12-280001039399us-gaap:CommonStockMember2019-12-292020-03-280001039399us-gaap:AdditionalPaidInCapitalMember2019-12-292020-03-280001039399us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-292020-03-280001039399us-gaap:RetainedEarningsMember2019-12-292020-03-280001039399us-gaap:CommonStockMember2020-03-280001039399us-gaap:AdditionalPaidInCapitalMember2020-03-280001039399us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-280001039399us-gaap:RetainedEarningsMember2020-03-280001039399us-gaap:CommonStockMember2018-12-290001039399us-gaap:AdditionalPaidInCapitalMember2018-12-290001039399us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-290001039399us-gaap:RetainedEarningsMember2018-12-2900010393992018-12-290001039399us-gaap:CommonStockMember2018-12-302019-03-300001039399us-gaap:AdditionalPaidInCapitalMember2018-12-302019-03-300001039399us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-302019-03-300001039399us-gaap:RetainedEarningsMember2018-12-302019-03-300001039399us-gaap:CommonStockMember2019-03-300001039399us-gaap:AdditionalPaidInCapitalMember2019-03-300001039399us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-300001039399us-gaap:RetainedEarningsMember2019-03-3000010393992019-03-30xbrli:pure0001039399us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberform:IntelMember2019-12-292020-03-280001039399us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberform:IntelMember2018-12-302019-03-300001039399us-gaap:CustomerConcentrationRiskMemberform:SamsungMemberus-gaap:RevenueFromContractWithCustomerMember2018-12-302019-03-300001039399us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2019-12-292020-03-280001039399us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2018-12-302019-03-300001039399us-gaap:CustomerConcentrationRiskMemberform:MajorCustomer1Memberus-gaap:AccountsReceivableMember2019-12-292020-03-280001039399us-gaap:CustomerConcentrationRiskMemberform:MajorCustomer2Memberus-gaap:AccountsReceivableMember2019-12-292020-03-280001039399us-gaap:CustomerConcentrationRiskMemberform:MajorCustomer2Memberus-gaap:AccountsReceivableMember2018-12-302019-12-280001039399us-gaap:CustomerConcentrationRiskMemberform:MajorCustomer1Memberus-gaap:AccountsReceivableMember2018-12-302019-12-280001039399us-gaap:CustomerConcentrationRiskMemberform:MajorCustomer3Memberus-gaap:AccountsReceivableMember2018-12-302019-12-280001039399form:FRTMember2019-10-090001039399form:FRTMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-03-2800010393992019-10-092019-10-090001039399us-gaap:FairValueInputsLevel3Member2020-03-280001039399us-gaap:DevelopedTechnologyRightsMemberform:FRTMember2019-10-090001039399us-gaap:DevelopedTechnologyRightsMemberform:FRTMember2019-10-092019-10-090001039399form:FRTMemberus-gaap:CustomerRelationshipsMember2019-10-090001039399form:FRTMemberus-gaap:CustomerRelationshipsMember2019-10-092019-10-090001039399form:FRTMemberus-gaap:OrderOrProductionBacklogMember2019-10-090001039399form:FRTMemberus-gaap:OrderOrProductionBacklogMember2019-10-092019-10-090001039399us-gaap:TradeNamesMemberform:FRTMember2019-10-090001039399us-gaap:TradeNamesMemberform:FRTMember2019-10-092019-10-090001039399form:FRTMember2019-10-092019-10-09iso4217:EUR0001039399form:FRTMembersrt:MinimumMember2019-10-090001039399srt:MaximumMemberform:FRTMember2019-10-090001039399form:FRTTermLoanMember2019-10-250001039399form:ProbeCardsSegmentMember2018-12-290001039399form:SystemsSegmentMember2018-12-290001039399form:ProbeCardsSegmentMember2018-12-302019-12-280001039399form:SystemsSegmentMember2018-12-302019-12-2800010393992018-12-302019-12-280001039399form:ProbeCardsSegmentMember2019-12-280001039399form:SystemsSegmentMember2019-12-280001039399form:ProbeCardsSegmentMember2019-12-292020-03-280001039399form:SystemsSegmentMember2019-12-292020-03-280001039399form:ProbeCardsSegmentMember2020-03-280001039399form:SystemsSegmentMember2020-03-280001039399form:ExistingDevelopedTechnologiesMember2020-03-280001039399form:ExistingDevelopedTechnologiesMember2019-12-280001039399us-gaap:TradeNamesMember2020-03-280001039399us-gaap:TradeNamesMember2019-12-280001039399us-gaap:CustomerRelationshipsMember2020-03-280001039399us-gaap:CustomerRelationshipsMember2019-12-280001039399us-gaap:OrderOrProductionBacklogMember2020-03-280001039399us-gaap:OrderOrProductionBacklogMember2019-12-280001039399us-gaap:CostOfSalesMember2019-12-292020-03-280001039399us-gaap:CostOfSalesMember2018-12-302019-03-300001039399us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-12-292020-03-280001039399us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-12-302019-03-300001039399us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2020-03-280001039399us-gaap:MoneyMarketFundsMember2020-03-280001039399us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2020-03-280001039399us-gaap:USTreasuryBillSecuritiesMember2020-03-280001039399us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2020-03-280001039399us-gaap:CertificatesOfDepositMember2020-03-280001039399us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-03-280001039399us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-03-280001039399us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2020-03-280001039399us-gaap:CorporateBondSecuritiesMember2020-03-280001039399us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-03-280001039399us-gaap:CommercialPaperMember2020-03-280001039399us-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:FairValueInputsLevel2Member2020-03-280001039399us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2020-03-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2020-03-280001039399us-gaap:ForeignExchangeContractMember2020-03-280001039399us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2020-03-280001039399us-gaap:InterestRateSwapMember2020-03-280001039399us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2019-12-280001039399us-gaap:MoneyMarketFundsMember2019-12-280001039399us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2019-12-280001039399us-gaap:USTreasuryBillSecuritiesMember2019-12-280001039399us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2019-12-280001039399us-gaap:CertificatesOfDepositMember2019-12-280001039399us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-280001039399us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-280001039399us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2019-12-280001039399us-gaap:CorporateBondSecuritiesMember2019-12-280001039399us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2019-12-280001039399us-gaap:CommercialPaperMember2019-12-280001039399us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2019-12-280001039399us-gaap:ForeignExchangeContractMember2019-12-280001039399us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2019-12-280001039399us-gaap:InterestRateSwapMember2019-12-280001039399us-gaap:FairValueInputsLevel1Member2019-12-280001039399us-gaap:FairValueInputsLevel2Member2019-12-280001039399us-gaap:FairValueInputsLevel3Member2019-12-280001039399us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-292020-03-280001039399us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberform:OtherIncomeExpenseNetMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-292020-03-280001039399us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-302019-03-300001039399us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberform:OtherIncomeExpenseNetMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-302019-03-30iso4217:TWD0001039399us-gaap:ForeignExchangeForwardMembercurrency:EURus-gaap:LongMember2020-03-280001039399currency:JPYus-gaap:ForeignExchangeForwardMemberus-gaap:ShortMember2020-03-280001039399currency:KRWus-gaap:ForeignExchangeForwardMemberus-gaap:ShortMember2020-03-280001039399us-gaap:ForeignExchangeForwardMember2020-03-280001039399us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-12-292020-03-280001039399us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2018-12-302019-03-300001039399us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-292020-03-280001039399us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2019-12-292020-03-280001039399us-gaap:ForeignExchangeForwardMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-292020-03-280001039399us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-12-292020-03-280001039399us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-302019-03-300001039399us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2018-12-302019-03-300001039399us-gaap:ForeignExchangeForwardMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-302019-03-300001039399us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2018-12-302019-03-300001039399us-gaap:FairValueMeasurementsNonrecurringMember2020-03-280001039399us-gaap:FairValueMeasurementsNonrecurringMember2019-12-280001039399form:EquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-12-280001039399form:EquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-12-292020-03-280001039399form:EquityIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2020-03-280001039399form:EquityIncentivePlanMember2019-12-280001039399form:EquityIncentivePlanMember2019-12-292020-03-280001039399form:EquityIncentivePlanMember2020-03-280001039399us-gaap:EmployeeStockMember2019-12-292020-03-280001039399us-gaap:EmployeeStockMember2020-03-280001039399us-gaap:ResearchAndDevelopmentExpenseMember2019-12-292020-03-280001039399us-gaap:ResearchAndDevelopmentExpenseMember2018-12-302019-03-300001039399us-gaap:RestrictedStockMember2020-03-280001039399us-gaap:RestrictedStockMember2019-12-292020-03-280001039399form:PerformanceRestrictedStockUnitsMember2020-03-280001039399form:PerformanceRestrictedStockUnitsMember2019-12-292020-03-280001039399srt:MinimumMember2020-03-280001039399srt:MaximumMember2020-03-280001039399us-gaap:AutomobilesMembersrt:MinimumMember2020-03-280001039399srt:MaximumMemberus-gaap:AutomobilesMember2020-03-280001039399srt:ScenarioForecastMember2020-03-292020-12-260001039399srt:ScenarioForecastMember2020-12-272021-12-250001039399srt:ScenarioForecastMember2021-12-262022-12-25form:segment0001039399us-gaap:OperatingSegmentsMemberform:ProbeCardsSegmentMember2019-12-292020-03-280001039399us-gaap:OperatingSegmentsMemberform:SystemsSegmentMember2019-12-292020-03-280001039399us-gaap:CorporateAndOtherMember2019-12-292020-03-280001039399us-gaap:OperatingSegmentsMemberform:ProbeCardsSegmentMember2018-12-302019-03-300001039399us-gaap:OperatingSegmentsMemberform:SystemsSegmentMember2018-12-302019-03-300001039399us-gaap:CorporateAndOtherMember2018-12-302019-03-300001039399form:ProbeCardsSegmentMemberform:FoundryLogicProductGroupMember2019-12-292020-03-280001039399form:SystemsSegmentMemberform:FoundryLogicProductGroupMember2019-12-292020-03-280001039399form:FoundryLogicProductGroupMember2019-12-292020-03-280001039399form:ProbeCardsSegmentMemberform:FoundryLogicProductGroupMember2018-12-302019-03-300001039399form:SystemsSegmentMemberform:FoundryLogicProductGroupMember2018-12-302019-03-300001039399form:FoundryLogicProductGroupMember2018-12-302019-03-300001039399form:ProbeCardsSegmentMemberform:DRAMProductGroupMember2019-12-292020-03-280001039399form:DRAMProductGroupMemberform:SystemsSegmentMember2019-12-292020-03-280001039399form:DRAMProductGroupMember2019-12-292020-03-280001039399form:ProbeCardsSegmentMemberform:DRAMProductGroupMember2018-12-302019-03-300001039399form:DRAMProductGroupMemberform:SystemsSegmentMember2018-12-302019-03-300001039399form:DRAMProductGroupMember2018-12-302019-03-300001039399form:FlashProductGroupMemberform:ProbeCardsSegmentMember2019-12-292020-03-280001039399form:FlashProductGroupMemberform:SystemsSegmentMember2019-12-292020-03-280001039399form:FlashProductGroupMember2019-12-292020-03-280001039399form:FlashProductGroupMemberform:ProbeCardsSegmentMember2018-12-302019-03-300001039399form:FlashProductGroupMemberform:SystemsSegmentMember2018-12-302019-03-300001039399form:FlashProductGroupMember2018-12-302019-03-300001039399form:SystemsProductGroupMemberform:ProbeCardsSegmentMember2019-12-292020-03-280001039399form:SystemsProductGroupMemberform:SystemsSegmentMember2019-12-292020-03-280001039399form:SystemsProductGroupMember2019-12-292020-03-280001039399form:SystemsProductGroupMemberform:ProbeCardsSegmentMember2018-12-302019-03-300001039399form:SystemsProductGroupMemberform:SystemsSegmentMember2018-12-302019-03-300001039399form:SystemsProductGroupMember2018-12-302019-03-300001039399form:ProbeCardsSegmentMember2018-12-302019-03-300001039399form:SystemsSegmentMember2018-12-302019-03-300001039399form:ProbeCardsSegmentMemberus-gaap:TransferredAtPointInTimeMember2019-12-292020-03-280001039399form:SystemsSegmentMemberus-gaap:TransferredAtPointInTimeMember2019-12-292020-03-280001039399us-gaap:TransferredAtPointInTimeMember2019-12-292020-03-280001039399form:ProbeCardsSegmentMemberus-gaap:TransferredAtPointInTimeMember2018-12-302019-03-300001039399form:SystemsSegmentMemberus-gaap:TransferredAtPointInTimeMember2018-12-302019-03-300001039399us-gaap:TransferredAtPointInTimeMember2018-12-302019-03-300001039399form:ProbeCardsSegmentMemberus-gaap:TransferredOverTimeMember2019-12-292020-03-280001039399form:SystemsSegmentMemberus-gaap:TransferredOverTimeMember2019-12-292020-03-280001039399us-gaap:TransferredOverTimeMember2019-12-292020-03-280001039399form:ProbeCardsSegmentMemberus-gaap:TransferredOverTimeMember2018-12-302019-03-300001039399form:SystemsSegmentMemberus-gaap:TransferredOverTimeMember2018-12-302019-03-300001039399us-gaap:TransferredOverTimeMember2018-12-302019-03-300001039399form:ProbeCardsSegmentMembercountry:CN2019-12-292020-03-280001039399country:CNform:SystemsSegmentMember2019-12-292020-03-280001039399country:CN2019-12-292020-03-280001039399form:ProbeCardsSegmentMembercountry:CN2018-12-302019-03-300001039399country:CNform:SystemsSegmentMember2018-12-302019-03-300001039399country:CN2018-12-302019-03-300001039399form:ProbeCardsSegmentMembercountry:US2019-12-292020-03-280001039399form:SystemsSegmentMembercountry:US2019-12-292020-03-280001039399country:US2019-12-292020-03-280001039399form:ProbeCardsSegmentMembercountry:US2018-12-302019-03-300001039399form:SystemsSegmentMembercountry:US2018-12-302019-03-300001039399country:US2018-12-302019-03-300001039399form:ProbeCardsSegmentMembercountry:TW2019-12-292020-03-280001039399country:TWform:SystemsSegmentMember2019-12-292020-03-280001039399country:TW2019-12-292020-03-280001039399form:ProbeCardsSegmentMembercountry:TW2018-12-302019-03-300001039399country:TWform:SystemsSegmentMember2018-12-302019-03-300001039399country:TW2018-12-302019-03-300001039399form:ProbeCardsSegmentMembersrt:EuropeMember2019-12-292020-03-280001039399form:SystemsSegmentMembersrt:EuropeMember2019-12-292020-03-280001039399srt:EuropeMember2019-12-292020-03-280001039399form:ProbeCardsSegmentMembersrt:EuropeMember2018-12-302019-03-300001039399form:SystemsSegmentMembersrt:EuropeMember2018-12-302019-03-300001039399srt:EuropeMember2018-12-302019-03-300001039399country:KRform:ProbeCardsSegmentMember2019-12-292020-03-280001039399country:KRform:SystemsSegmentMember2019-12-292020-03-280001039399country:KR2019-12-292020-03-280001039399country:KRform:ProbeCardsSegmentMember2018-12-302019-03-300001039399country:KRform:SystemsSegmentMember2018-12-302019-03-300001039399country:KR2018-12-302019-03-300001039399country:JPform:ProbeCardsSegmentMember2019-12-292020-03-280001039399country:JPform:SystemsSegmentMember2019-12-292020-03-280001039399country:JP2019-12-292020-03-280001039399country:JPform:ProbeCardsSegmentMember2018-12-302019-03-300001039399country:JPform:SystemsSegmentMember2018-12-302019-03-300001039399country:JP2018-12-302019-03-300001039399srt:AsiaPacificMemberform:ProbeCardsSegmentMember2019-12-292020-03-280001039399srt:AsiaPacificMemberform:SystemsSegmentMember2019-12-292020-03-280001039399srt:AsiaPacificMember2019-12-292020-03-280001039399srt:AsiaPacificMemberform:ProbeCardsSegmentMember2018-12-302019-03-300001039399srt:AsiaPacificMemberform:SystemsSegmentMember2018-12-302019-03-300001039399srt:AsiaPacificMember2018-12-302019-03-300001039399form:ProbeCardsSegmentMemberform:RestOfTheWorldMember2019-12-292020-03-280001039399form:SystemsSegmentMemberform:RestOfTheWorldMember2019-12-292020-03-280001039399form:RestOfTheWorldMember2019-12-292020-03-280001039399form:ProbeCardsSegmentMemberform:RestOfTheWorldMember2018-12-302019-03-300001039399form:SystemsSegmentMemberform:RestOfTheWorldMember2018-12-302019-03-300001039399form:RestOfTheWorldMember2018-12-302019-03-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark one)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 28, 2020
Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 000-50307
FormFactor, Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Delaware | | 13-3711155 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
7005 Southfront Road, Livermore, California 94551
(Address of principal executive offices, including zip code)
(925) 290-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section12(b) of the Act:
| | | | | | | | | | | | | | | | | | | | |
| Title of each class | | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common stock, $0.001 par value | | | FORM | | Nasdaq Global Market |
______________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of the Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
| | | | | | | | | | | |
Large Accelerated Filer | ☒ | Accelerated Filer | ☐ |
| | | |
Non-accelerated Filer | ☐ | Smaller Reporting Company | ☐ |
| | | |
Emerging Growth Company | ☐ | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 4, 2020, 76,161,842 shares of the registrant’s common stock, par value $0.001 per share, were outstanding.
FORMFACTOR, INC.
FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 28, 2020
INDEX
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
FORMFACTOR, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
| | | | | | | | | | | |
| March 28, 2020 | | December 28, 2019 |
ASSETS | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 169,607 | | | $ | 144,545 | |
Marketable securities | 69,759 | | | 76,327 | |
Accounts receivable, net of allowance for doubtful accounts of $222 and $222 | 90,100 | | | 97,868 | |
Inventories, net | 78,983 | | | 83,258 | |
Restricted cash | 2,107 | | | 1,981 | |
| | | |
Prepaid expenses and other current assets | 15,699 | | | 15,064 | |
Total current assets | 426,255 | | | 419,043 | |
Restricted cash | 1,361 | | | 1,411 | |
Operating lease, right-of-use-assets | 36,212 | | | 31,420 | |
Property, plant and equipment, net of accumulated depreciation of $277,017 and $273,001 | 63,745 | | | 58,747 | |
Goodwill | 200,378 | | | 199,196 | |
Intangibles, net | 50,139 | | | 57,610 | |
Deferred tax assets | 70,273 | | | 71,252 | |
Other assets | 1,016 | | | 1,203 | |
Total assets | $ | 849,379 | | | $ | 839,882 | |
| | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
Current liabilities: | | | |
Accounts payable | $ | 40,139 | | | $ | 40,914 | |
Accrued liabilities | 29,175 | | | 36,439 | |
Current portion of term loans, net of unamortized issuance costs | 31,535 | | | 42,846 | |
| | | |
Deferred revenue | 9,830 | | | 9,810 | |
Operating lease liabilities | 6,815 | | | 6,551 | |
Total current liabilities | 117,494 | | | 136,560 | |
Term loan, less current portion, net of unamortized issuance costs | 13,642 | | | 15,639 | |
| | | |
Deferred tax liabilities | 6,095 | | | 6,986 | |
Long-term operating lease liabilities | 34,028 | | | 29,088 | |
Other liabilities | 11,703 | | | 10,612 | |
Total liabilities | 182,962 | | | 198,885 | |
| | | |
Stockholders’ equity: | | | |
Preferred stock, $0.001 par value: | | | |
10,000,000 shares authorized; no shares issued and outstanding | — | | | — | |
Common stock, $0.001 par value: | | | |
250,000,000 shares authorized; 76,158,251 and 75,764,990 shares issued and outstanding | 77 | | | 76 | |
Additional paid-in capital | 895,600 | | | 885,821 | |
Accumulated other comprehensive loss | (909) | | | (659) | |
Accumulated deficit | (228,351) | | | (244,241) | |
Total stockholders’ equity | 666,417 | | | 640,997 | |
Total liabilities and stockholders’ equity | $ | 849,379 | | | $ | 839,882 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
FORMFACTOR, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Revenues | $ | 160,753 | | | $ | 132,213 | | | | | |
Cost of revenues | 93,363 | | | 79,692 | | | | | |
Gross profit | 67,390 | | | 52,521 | | | | | |
Operating expenses: | | | | | | | |
Research and development | 21,267 | | | 19,723 | | | | | |
Selling, general and administrative | 27,693 | | | 25,184 | | | | | |
Total operating expenses | 48,960 | | | 44,907 | | | | | |
Operating income | 18,430 | | | 7,614 | | | | | |
Interest income | 685 | | | 580 | | | | | |
Interest expense | (318) | | | (595) | | | | | |
Other expense, net | (91) | | | (84) | | | | | |
Income before income taxes | 18,706 | | | 7,515 | | | | | |
Provision for income taxes | 2,816 | | | 2,032 | | | | | |
Net income | $ | 15,890 | | | $ | 5,483 | | | | | |
Net income per share: | | | | | | | |
Basic | $ | 0.21 | | | $ | 0.07 | | | | | |
Diluted | $ | 0.20 | | | $ | 0.07 | | | | | |
Weighted-average number of shares used in per share calculations: | | | | | | | |
Basic | 76,005 | | | 74,362 | | | | | |
Diluted | 78,510 | | | 76,009 | | | | | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
FORMFACTOR, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
(Unaudited)
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Net income | $ | 15,890 | | | $ | 5,483 | | | | | |
Other comprehensive loss, net of tax: | | | | | | | |
Translation adjustments and other | (399) | | | (917) | | | | | |
Unrealized gains (losses) on available-for-sale marketable securities | (27) | | | 151 | | | | | |
Unrealized gains (losses) on derivative instruments | 176 | | | (613) | | | | | |
Other comprehensive loss, net of tax | (250) | | | (1,379) | | | | | |
Comprehensive income | $ | 15,640 | | | $ | 4,104 | | | | | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
FORMFACTOR, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(In thousands, except shares)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Shares | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive Loss | | Accumulated Deficit | | Total |
| Three Months Ended March 28, 2020 | | | | | | | | | | |
Balances, December 28, 2019 | 75,764,990 | | | $ | 76 | | | $ | 885,821 | | | $ | (659) | | | $ | (244,241) | | | $ | 640,997 | |
Issuance of common stock under the Employee Stock Purchase Plan | 311,591 | | | — | | | 4,066 | | | — | | | — | | | 4,066 | |
Issuance of common stock pursuant to exercise of options | 55,769 | | | 1 | | | 446 | | | — | | | — | | | 447 | |
Issuance of common stock pursuant to vesting of restricted stock units, net of stock withheld for tax | 25,901 | | | — | | | (385) | | | — | | | — | | | (385) | |
| | | | | | | | | | | |
Stock-based compensation | — | | | — | | | 5,652 | | | — | | | — | | | 5,652 | |
Other comprehensive loss | — | | | — | | | — | | | (250) | | | — | | | (250) | |
Net income | — | | | — | | | — | | | — | | | 15,890 | | | 15,890 | |
Balances, March 28, 2020 | 76,158,251 | | | $ | 77 | | | $ | 895,600 | | | $ | (909) | | | $ | (228,351) | | | $ | 666,417 | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Shares | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive Loss | | Accumulated Deficit | | Total |
| Three Months Ended March 30, 2019 | | | | | | | | | | |
Balances, December 29, 2018 | 74,139,712 | | | $ | 74 | | | $ | 862,897 | | | $ | 780 | | | $ | (283,587) | | | $ | 580,164 | |
Issuance of common stock under the Employee Stock Purchase Plan | 301,497 | | | — | | | 3,670 | | | — | | | — | | | 3,670 | |
Issuance of common stock pursuant to exercise of options for cash | 19,207 | | | — | | | 90 | | | — | | | — | | | 90 | |
Issuance of common stock pursuant to vesting of restricted stock units, net of stock withheld for tax | 28,082 | | | — | | | (302) | | | — | | | — | | | (302) | |
| | | | | | | | | | | |
Stock-based compensation | — | | | — | | | 5,262 | | | — | | | — | | | 5,262 | |
| | | | | | | | | | | |
Other comprehensive loss | — | | | — | | | — | | | (1,379) | | | — | | | (1,379) | |
Net income | — | | | — | | | — | | | — | | | 5,483 | | | 5,483 | |
Balances, March 30, 2019 | 74,488,498 | | | $ | 74 | | | $ | 871,617 | | | $ | (599) | | | $ | (278,104) | | | $ | 592,988 | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
FORMFACTOR, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| | | | | | | | | | | |
| Three Months Ended | | |
| March 28, 2020 | | March 30, 2019 |
Cash flows from operating activities: | | | |
Net income | $ | 15,890 | | | $ | 5,483 | |
Adjustments to reconcile net income to net cash provided by operating activities: | | | |
Depreciation | 4,561 | | | 3,947 | |
Amortization | 7,263 | | | 7,090 | |
Accretion of discount on investments | (28) | | | (71) | |
Reduction in the carrying amount of right-of-use assets | 1,511 | | | 1,277 | |
Stock-based compensation expense | 5,623 | | | 5,295 | |
Amortization of debt issuance costs | 19 | | | 51 | |
Deferred income tax benefit | (198) | | | — | |
Provision for excess and obsolete inventories | 3,287 | | | 2,725 | |
Loss on disposal of long-lived assets | 204 | | | 118 | |
| | | |
Loss on derivative instruments | 676 | | | 59 | |
Foreign currency transaction (losses) gains | (266) | | | 121 | |
Changes in assets and liabilities: | | | |
Accounts receivable | 7,803 | | | 13,805 | |
Inventories | 928 | | | (8,658) | |
Prepaid expenses and other current assets | (240) | | | 2,167 | |
| | | |
Other assets | 194 | | | (564) | |
Accounts payable | 763 | | | (7,148) | |
Accrued liabilities | (6,970) | | | (6,275) | |
| | | |
Other liabilities | 33 | | | 32 | |
Deferred revenues | (123) | | | 1,931 | |
Operating lease liabilities | (1,591) | | | (1,690) | |
| | | |
Net cash provided by operating activities | 39,339 | | | 20,638 | |
Cash flows from investing activities: | | | | |
Acquisition of property, plant and equipment | (12,050) | | | (6,028) | |
Proceeds from sale of a subsidiary | 40 | | | 28 | |
| | | |
Purchases of marketable securities | (16,441) | | | (12,382) | |
Proceeds from maturities and sales of marketable securities | 23,009 | | | 9,050 | |
| | | |
Net cash used in investing activities | (5,442) | | | (9,332) | |
Cash flows from financing activities: | | | | |
Proceeds from issuances of common stock | 4,513 | | | 3,870 | |
| | | |
Tax withholdings related to net share settlements of equity awards | (385) | | | (302) | |
| | | |
Principal repayments on term loans | (13,199) | | | (7,500) | |
| | | |
Net cash used in financing activities | (9,071) | | | (3,932) | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 312 | | | (207) | |
Net increase in cash, cash equivalents and restricted cash | 25,138 | | | 7,167 | |
Cash, cash equivalents and restricted cash, beginning of period | 147,937 | | | 100,546 | |
Cash, cash equivalents and restricted cash, end of period | $ | 173,075 | | | $ | 107,713 | |
Non-cash investing and financing activities: | | | |
| | | |
| | | |
| | | |
Change in accounts payable and accrued liabilities related to property, plant and equipment purchases | $ | 2,116 | | | $ | (1,253) | |
Operating lease, right-of-use assets obtained in exchange for lease obligations | 6,307 | | | 35,713 | |
Supplemental disclosure of cash flow information: | | | |
Cash paid for income taxes, net | $ | 2,419 | | | $ | 1,082 | |
Cash paid for interest | 291 | | | 302 | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
FORMFACTOR, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1 — Basis of Presentation and New Accounting Pronouncements
Basis of Presentation
The accompanying condensed consolidated financial information of FormFactor, Inc. is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The financial information as of December 28, 2019 is derived from our 2019 Annual Report on Form 10-K. The condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2019 Annual Report on Form 10-K filed with the SEC on February 21, 2020. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.
Fiscal Year
We operate on a 52/53 week fiscal year, whereby the fiscal year ends on the last Saturday of December. Fiscal 2020 and 2019 each contain 52 weeks and the three months ended March 28, 2020 and March 30, 2019 each contained 13 weeks. Fiscal 2020 will end on December 26, 2020.
Critical Accounting Policies
Our critical accounting policies have not changed during the three months ended March 28, 2020 from those disclosed in our Annual Report on Form 10-K for the year ended December 28, 2019.
New Accounting Pronouncements
ASU 2016-13
In June 2016, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, "Measurement of Credit Losses on Financial Instruments (Topic 326)." The provisions of this standard require financial assets measured at amortized cost to be presented at the net amount expected to be collected. An allowance account would be established to present the net carrying value at the amount expected to be collected. ASU 2016-13 also provides that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The guidance was amended through various ASU's subsequent to ASU 2016-13, all of which was effective for us beginning fiscal 2020. We adopted ASU 2016-13 on a prospective basis on December 29, 2019, the first day of fiscal 2020. The adoption did not have a material effect on our financial position, results of operations or cash flows.
ASU 2018-15
In August 2018, the FASB issued ASU 2018-15, "Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." The new guidance clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2019. We adopted ASU 2018-15 on a prospective basis on December 29, 2019, the first day of fiscal 2020. The adoption did not have a material effect on our financial position, results of operations or cash flows.
ASU 2019-12
In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740),” which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption of the amendments is permitted, including adoption in any interim period for which financial statements have not yet been issued. Depending on the amendment, adoption may be applied on the retrospective, modified retrospective or prospective basis. We have not yet determined the impact of this standard on our financial position, results of operations or cash flows.
Note 2 — Concentration of Credit and Other Risks
Each of the following customers accounted for 10% or more of our revenues for the periods indicated:
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Intel Corporation | 36.2 | % | | 21.3 | % | | | | |
| | | | | | | |
| | | | | | | |
Samsung Electronics., LTD. | * | | | 13.8 | | | | | |
| | | | | | | |
| 36.2 | % | | 35.1 | % | | | | |
*Represents less than 10% of total revenues.
At March 28, 2020, two customers accounted for 27.7% and 15.3% of gross accounts receivable, respectively. At December 28, 2019, three customers accounted for 25.7%, 15.1% and 11.5% of gross accounts receivable, respectively.
Note 3 — Inventories, net
Inventories are stated at the lower of cost (principally standard cost, which approximates actual cost on a first in, first out basis) or net realizable value.
Inventories, net, consisted of the following (in thousands):
| | | | | | | | | | | |
| March 28, 2020 | | December 28, 2019 |
Raw materials | $ | 36,468 | | | $ | 38,528 | |
Work-in-progress | 27,927 | | | 29,720 | |
Finished goods | 14,588 | | | 15,010 | |
| $ | 78,983 | | | $ | 83,258 | |
Note 4 — Acquisition
On October 9, 2019, we acquired 100% of the shares of FRT GmbH ("FRT"), a German-based company, for total consideration of $26.9 million, net of cash acquired of $1.7 million. The fair value of the purchase consideration was comprised of a $22.2 million cash payment and $6.5 million of contingent consideration.
We estimated the acquisition price and the allocation of fair value to assets acquired and liabilities assumed as of the acquisition date, October 9, 2019. We subsequently made certain immaterial adjustments to the acquisition price allocation related to acquired assets and assumed liabilities, including to intangibles assets. Our purchase accounting remains open at March 28, 2020, subject to finalization of the fair value of certain acquired assets and liabilities. The estimated fair value of assets acquired, including goodwill and intangibles, and liabilities assumed is as follows (in thousands):
| | | | | | | | | |
| | | | | Amount |
Cash and cash equivalents | | | | | $ | 1,683 | |
Accounts receivable | | | | | 3,057 | |
Inventory | | | | | 2,643 | |
Property, plant and equipment | | | | | 696 | |
Operating lease, right of use assets | | | | | 335 | |
Prepaid expenses and other current assets | | | | | 838 | |
Tangible assets acquired | | | | | 9,252 | |
Customer deposits | | | | | (2,093) | |
Accounts payable and accrued liabilities | | | | | (1,179) | |
Operating lease liabilities | | | | | (335) | |
Deferred tax liabilities | | | | | (5,843) | |
Total tangible assets acquired and liabilities assumed | | | | | (198) | |
Intangible assets | | | | | 17,429 | |
Goodwill | | | | | 11,392 | |
Net Assets Acquired | | | | | $ | 28,623 | |
The intangible assets as of the closing date of the acquisition included (in thousands):
| | | | | | | | | | | |
| Amount | | Weighted Average Useful Life (in years) |
Developed technologies | $ | 12,505 | | | 8.0 |
Customer relationships | 3,071 | | | 6.0 |
Backlog | 1,645 | | | 0.5 |
Trade names | 208 | | | 2.0 |
Total intangible assets | $ | 17,429 | | | 7.0 |
Indications of fair value of the intangible assets acquired in connection with the acquisition were determined using either the income, market or replacement cost methodologies. The intangible assets are being amortized over periods which reflect the pattern in which economic benefits of the assets are expected to be realized.
The contingent consideration is a cash amount equal to 1.5x Earnings Before Interest and Tax ("EBIT") as defined in the purchase agreement, from a minimum of zero up to a maximum of €10.3 million, payable subject to the performance of the acquired business in calendar 2020. We estimated the fair value of contingent consideration using a probability weighted approach. Key assumptions in determining the fair value of contingent consideration include estimating the probability of achieving certain EBIT levels and discounting at an appropriate discount rate.
This acquisition strengthens our leadership in test and measurement by expanding our addressable market into 3D hybrid surface metrology and extending the optical applications scope of our existing Systems segment.
Separate from the purchase agreement, on October 25, 2019, we entered into a term loan agreement with a lender for an aggregate amount of $23.4 million to finance the acquisition. The term loan agreement has not changed during the three months ended March 28, 2020 from that disclosed in our Annual Report on Form 10-K for the year ended December 28, 2019.
Identifiable Intangible Assets
Valuation of intangible assets involves multiple assumptions. The key assumptions are described below.
Developed technologies acquired primarily consists of existing technology related to hybrid 3D surface metrology measurement equipment. We valued the developed technologies using the multi-period excess earnings method under the income approach. Using this approach, the estimated fair values were calculated using expected future cash flows from specific products discounted to their net present values at an appropriate risk-adjusted rate of return.
Customer relationships represent the fair value of future projected revenues that will be derived from the sale of products to FRT's existing customers. We valued customer relationships using the incremental cash flow method. This method estimates value based on the incremental cash flow afforded by having the customers relationships in place on the acquisition date versus having no relationships in place and needing to replicate or replace those relationships. The incremental cash flows are then discounted to a present value to arrive at an estimate of fair value for this asset class.
Backlog represents business under existing contractual obligations. Expected cash flow from backlog was valued on a direct cash flow basis.
The identified trade names intangibles relate to the estimated fair value of future cash flows related to the FRT brand. We valued trade names by applying the relief-from-royalty method under the income approach. This method is based on the application of a royalty rate to forecasted revenue under the trade name.
Goodwill
The excess of purchase price over the fair value assigned to the assets acquired and liabilities assumed represents the amount of goodwill resulting from the acquisition. We believe the factors that contributed to goodwill include synergies that are specific to our consolidated business, such as cost savings and operational efficiencies, and the acquisition of a talented workforce that expands our expertise in business development and commercializing semiconductor test products, none of which qualify for recognition as a separate intangible asset. We do not expect any portion of this goodwill to be deductible for tax purposes. The goodwill attributable to the acquisition was recorded as a non-current asset and is not amortized, but is subject to an annual review for impairment.
The goodwill arising from the acquisition was allocated to the FRT reporting unit within the Systems reportable segment.
We have not presented unaudited combined pro forma financial information as the FRT acquisition was not significant to our consolidated results of operations and financial position.
Note 5 — Goodwill and Intangible Assets
Goodwill by reportable segment was as follows (in thousands):
| | | | | | | | | | | | | | | | | | |
| | Probe Cards | | Systems | | Total |
Goodwill, gross, as of December 29, 2018 | | $ | 172,482 | | | $ | 16,732 | | | $ | 189,214 | |
Addition - FRT GmbH Acquisition | | — | | | 10,148 | | | 10,148 | |
Foreign currency translation | | — | | | (166) | | | (166) | |
Goodwill, gross, as of December 28, 2019 | | 172,482 | | | 26,714 | | | 199,196 | |
Addition - FRT GmbH Acquisition | | — | | | 1,264 | | | 1,264 | |
Foreign currency translation | | — | | | (82) | | | (82) | |
Goodwill, gross, as of March 28, 2020 | | $ | 172,482 | | | $ | 27,896 | | | $ | 200,378 | |
No goodwill impairments have been recorded as of March 28, 2020 and December 28, 2019.
Intangible assets were as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | March 28, 2020 | | | | | | December 28, 2019 | | | | |
Intangible Assets | | Gross | | Accumulated Amortization | | Net | | Gross | | Accumulated Amortization | | Net |
Developed technologies | | $ | 155,792 | | | $ | 121,091 | | | $ | 34,701 | | | $ | 154,951 | | | $ | 116,138 | | | $ | 38,813 | |
Trade names | | 7,809 | | | 7,046 | | | 763 | | | 7,816 | | | 6,976 | | | 840 | |
Customer relationships | | 43,170 | | | 28,495 | | | 14,675 | | | 44,229 | | | 27,057 | | | 17,172 | |
Backlog | | 1,670 | | | 1,670 | | | — | | | 1,676 | | | 891 | | | 785 | |
| | $ | 208,441 | | | $ | 158,302 | | | $ | 50,139 | | | $ | 208,672 | | | $ | 151,062 | | | $ | 57,610 | |
Amortization expense was included in our Condensed Consolidated Statements of Income as follows (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Cost of revenues | $ | 5,750 | | | $ | 4,719 | | | | | |
Selling, general and administrative | 1,513 | | | 2,371 | | | | | |
| $ | 7,263 | | | $ | 7,090 | | | | | |
The estimated future amortization of intangible assets is as follows (in thousands):
| | | | | | |
Fiscal Year | | Amount |
Remainder of 2020 | | | $ | 19,021 | |
2021 | | | 14,767 | |
2022 | | | 5,585 | |
2023 | | | 3,846 | |
2024 | | 2,107 | |
Thereafter | | 4,813 | |
| | $ | 50,139 | |
Note 6 — Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):
| | | | | | | | | | | |
| March 28, 2020 | | December 28, 2019 |
Accrued compensation and benefits | $ | 18,435 | | | $ | 21,329 | |
Accrued income and other taxes | 4,519 | | | 6,846 | |
Accrued warranty | 1,918 | | | 1,942 | |
Accrued employee stock purchase plan contributions withheld | 1,585 | | | 3,331 | |
Other accrued expenses | 2,718 | | | | 2,991 | |
| $ | 29,175 | | | $ | 36,439 | |
Note 7 — Fair Value and Derivative Instruments
Whenever possible, the fair values of our financial assets and liabilities are determined using quoted market prices of identical securities or quoted market prices of similar securities from active markets. The three levels of inputs that may be used to measure fair value are as follows:
•Level 1 valuations are obtained from real-time quotes for transactions in active exchange markets involving identical securities;
•Level 2 valuations utilize significant observable inputs, such as quoted prices for similar assets or liabilities, quoted prices near the reporting date in markets that are less active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
•Level 3 valuations utilize unobservable inputs to the valuation methodology and include our own data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.
We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 during the three months ended March 28, 2020 or the year ended December 28, 2019.
The carrying values of Cash, Accounts receivable, net, Restricted cash, Prepaid expenses and other current assets, Accounts payable, Accrued liabilities, and Current portion of term loans, net of unamortized issuance costs approximate fair value due to their short maturities.
No changes were made to our valuation techniques during the first three months of fiscal 2020.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Assets and liabilities measured at fair value on a recurring basis were as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
March 28, 2020 | | Level 1 | | Level 2 | | Level 3 | | Total |
Assets: | | | | | | | | |
Cash equivalents: | | | | | | | | |
Money market funds | | $ | 74,992 | | | $ | — | | | $ | — | | | $ | 74,992 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Marketable securities: | | | | | | | | | | | | |
U.S. treasuries | | 30,873 | | | — | | | — | | | 30,873 | |
Certificates of deposit | | — | | | 3,841 | | | — | | | 3,841 | |
U.S. agency securities | | — | | | 3,751 | | | — | | | 3,751 | |
Corporate bonds | | — | | | 28,657 | | | — | | | 28,657 | |
Commercial paper | | — | | | 2,637 | | | — | | | 2,637 | |
| | 30,873 | | | 38,886 | | | — | | | 69,759 | |
Foreign exchange derivative contracts | | — | | | 4 | | | — | | | 4 | |
| | | | | | | | |
Total assets | | $ | 105,865 | | | $ | 38,890 | | | $ | — | | | $ | 144,755 | |
Liabilities: | | | | | | | | |
Foreign exchange derivative contracts | | $ | — | | | | $ | (154) | | | | $ | — | | | | $ | (154) | |
Interest rate swap derivative contracts | | | — | | | | (93) | | | | — | | | | (93) | |
Contingent consideration | | — | | | | — | | | | (6,515) | | | | (6,515) | |
Total liabilities | | $ | — | | | | $ | (247) | | | | $ | (6,515) | | | | $ | (6,762) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
December 28, 2019 | | Level 1 | | Level 2 | | Level 3 | | Total |
Assets: | | | | | | | | |
Cash equivalents: | | | | | | | | |
Money market funds | | $ | 17,056 | | | $ | — | | | $ | — | | | $ | 17,056 | |
| | | | | | | | |
| | | | | | | | |
Marketable securities: | | | | | | | | |
U.S. treasuries | | 10,468 | | | — | | | — | | | 10,468 | |
Certificates of deposit | | — | | | 3,590 | | | — | | | 3,590 | |
U.S. agency securities | | — | | | 24,430 | | | — | | | 24,430 | |
Corporate bonds | | — | | | 33,928 | | | — | | | 33,928 | |
Commercial paper | | — | | | 3,911 | | | — | | | 3,911 | |
| | 10,468 | | | 65,859 | | | — | | | 76,327 | |
Foreign exchange derivative contracts | | — | | | 41 | | | — | | | 41 | |
Interest rate swap derivative contracts | | — | | | 26 | | | — | | | 26 | |
Total assets | | $ | 27,524 | | | $ | 65,926 | | | $ | — | | | $ | 93,450 | |
Liabilities: | | | | | | | | |
Foreign exchange derivative contracts | | $ | — | | | | $ | (240) | | | | $ | — | | | | $ | (240) | |
Contingent consideration | | — | | | | — | | | | (5,364) | | | | (5,364) | |
Total liabilities | | $ | — | | | | $ | (240) | | | | $ | (5,364) | | | | $ | (5,604) | |
Cash Equivalents
The fair value of our cash equivalents is determined based on quoted market prices for similar or identical securities.
Marketable Securities
We classify our marketable securities as available-for-sale and value them utilizing a market approach. Our investments are priced by pricing vendors who provide observable inputs for their pricing without applying significant judgment. Broker pricing is used mainly when a quoted price is not available, the investment is not priced by our pricing vendors or when a broker price is more reflective of fair value. Our broker-priced investments are categorized as Level 2 investments because fair value is based on similar assets without applying significant judgments. In addition, all investments have a sufficient trading volume to demonstrate that the fair value is appropriate.
Unrealized gains and losses were immaterial and were recorded as a component of Accumulated other comprehensive income in our Condensed Consolidated Balance Sheets. We did not have any other-than-temporary unrealized gains or losses at either period end included in these financial statements.
Contingent Consideration
Contingent consideration, arising from the acquisition of FRT (see Note 4), is a cash amount equal to 1.5x EBIT as defined in the purchase agreement, up to a maximum of €10.3 million, payable subject to the performance of the acquired business in calendar 2020. We estimated the fair value of contingent consideration using a probability weighted approach. Key assumptions in determining the fair value of contingent consideration include estimating the probability of achieving certain EBIT levels and discounting at an appropriate discount rate. Contingent consideration as of March 28, 2020 was $6.5 million and which increased by $1.1 million from $5.4 million as of December 28, 2019 as a result of subsequent immaterial adjustments.
Interest Rate Swaps
The fair value of our interest rate swap contracts is determined at the end of each reporting period based on valuation models that use interest rate yield curves as inputs. For accounting purposes, our interest rate swap contracts qualify for, and are designated as, cash flow hedges. The cash flows associated with the interest rate swaps are reported in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows and the fair value of the interest rate swap contracts are recorded within Prepaid expenses and other current assets in our Condensed Consolidated Balance Sheets.
The impact of the interest rate swaps on our Condensed Consolidated Statements of Income was as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) | | Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) | | Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) | | Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion) | | Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion) |
Three Months Ended March 28, 2020 | | $ | (96) | | | Interest expense, net | | $ | 22 | | | Interest expense, net | | $ | — | |
Three Months Ended March 30, 2019 | | $ | (28) | | | Interest expense, net | | $ | (208) | | | Interest expense, net | | $ | — | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
Foreign Exchange Derivative Contracts
We operate and sell our products in various global markets. As a result, we are exposed to changes in foreign currency exchange rates. We utilize foreign currency forward contracts to hedge against future movements in foreign exchange rates that affect certain existing foreign currency denominated assets and liabilities and forecasted foreign currency revenue and expense transactions. Under this program, our strategy is to have increases or decreases in our foreign currency exposures mitigated by gains or losses on the foreign currency forward contracts in order to mitigate the risks and volatility associated with foreign currency transaction gains or losses.
We do not use derivative financial instruments for speculative or trading purposes. For accounting purposes, certain of our foreign currency forward contracts are not designated as hedging instruments and, accordingly, we record the fair value of these contracts as of the end of our reporting period in our Condensed Consolidated Balance Sheets with changes in fair value recorded within Other expense, net in our Condensed Consolidated Statement of Income for both realized and unrealized gains and losses. Certain of our foreign currency forward contracts are designated as cash flow hedges, and, accordingly, we record the fair value of these contracts as of the end of our reporting period in our Condensed Consolidated Balance Sheets with changes in fair value recorded as a component of Accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings, and in the same line item on the Condensed Consolidated Statements of Income as the impact of the hedge transaction. At March 28, 2020, we expect to reclassify $0.2 million of the amount accumulated in Other comprehensive loss to earnings during the next 12 months, due to the recognition in earnings of the hedged forecasted transactions.
The fair value of our foreign exchange derivative contracts was determined based on current foreign currency exchange rates and forward points. All of our foreign exchange derivative contracts outstanding at March 28, 2020 will mature by the second quarter of fiscal 2021.
The following table provides information about our foreign currency forward contracts outstanding as of March 28, 2020 (in thousands):
| | | | | | | | | | | | | | | | | | | | |
Currency | | Contract Position | | Contract Amount (Local Currency)
| | Contract Amount (U.S. Dollars)
|
Euro Dollar | | Buy | | (3,061) | | | $ | (3,557) | |
Japanese Yen | | Sell | | 1,346,506 | | | 12,503 | |
Korean Won | | Buy | | (2,526,325) | | | (2,088) | |
| | | | | | |
| | | | | | |
Total USD notional amount of outstanding foreign exchange contracts | | | | | | $ | 6,858 | |
Our foreign currency contracts are classified within Level 2 of the fair value hierarchy as they are valued using pricing models that utilize observable market inputs.
The impact of foreign exchange derivative contracts not designated as cash flow hedges on our Condensed Consolidated Statements of Income was as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Amount of Gain (Loss) Recognized on Derivatives | | | | | | |
| | | | Three Months Ended | | | | | | |
Derivatives Not Designated as Hedging Instruments | | Location of Gain (Loss) Recognized on Derivatives | | March 28, 2020 | | March 30, 2019 | | | | |
Foreign exchange forward contracts | | Other expense, net | | $ | (115) | | | $ | 314 | | | | | |
The impact of foreign exchange derivative contracts designated as cash flow hedges on our Condensed Consolidated Statements of Income was as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Amount of Loss Recognized in Accumulated OCI on Derivative | | Location of Loss Reclassified from Accumulated OCI into Income | | Amount of Loss Reclassified from Accumulated OCI into Income | | | | |
Three Months Ended March 28, 2020 | | $ | (3) | | | Cost of revenues | | | $ | (120) | | | | | |
| | | | Research and development | | (18) | | | | | |
| | | | Selling, general and administrative | | (43) | | | | | |
| | | | | | $ | (181) | | | | | |
| | | | | | | | | | |
Three Months Ended March 30, 2019 | | $ | (435) | | | Cost of revenues | | | $ | (32) | | | | | |
| | | | Research and development | | (19) | | | | | |
| | | | Selling, general and administrative | | (7) | | | | | |
| | | | | | $ | (58) | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
We measure and report our non-financial assets such as Property, plant and equipment, Goodwill and Intangible assets at fair value on a non-recurring basis if we determine these assets to be impaired or in the period when we make a business acquisition. Other than as discussed in Note 4, there were no assets or liabilities measured at fair value on a nonrecurring basis during the three months ended March 28, 2020 or March 30, 2019.
Note 8 — Warranty
We offer warranties on certain products and record a liability for the estimated future costs associated with warranty claims at the time revenue is recognized. The warranty liability is based upon historical experience and our estimate of the level of future costs. While we engage in product quality programs and processes, our warranty obligation is affected by product failure rates, material usage and service delivery costs. We continuously monitor product returns for warranty and maintain a reserve for the related expenses based upon our historical experience and any specifically identified failures. As we sell new products to our customers, we must exercise considerable judgment in estimating the expected failure rates. This estimating process is based on historical experience of similar products, as well as various other assumptions that we believe to be reasonable under the circumstances. We provide for the estimated cost of product warranties at the time revenue is recognized as a component of Cost of revenues in our Condensed Consolidated Statement of Income.
Changes in our warranty liability were as follows (in thousands):
| | | | | | | | | | | |
| Three Months Ended | | |
| March 28, 2020 | | March 30, 2019 |
Balance at beginning of period | $ | 1,942 | | | $ | 2,102 | |
Accruals | 660 | | | 889 | |
Settlements | (684) | | | (970) | |
Balance at end of period | $ | 1,918 | | | $ | 2,021 | |
Note 9 — Stockholders’ Equity and Stock-Based Compensation
Restricted Stock Units
Restricted stock unit ("RSU") activity under our equity incentive plan was as follows:
| | | | | | | | | | | |
| Units | | Weighted Average Grant Date Fair Value |
RSUs at December 28, 2019 | 3,069,000 | | | $ | 14.30 | |
Awards granted | | 16,000 | | | 26.05 | |
Awards vested | | (43,604) | | | 12.70 | |
Awards forfeited | (20,291) | | | 14.25 | |
RSUs at March 28, 2020 | | 3,021,105 | | | $ | 14.39 | |
The total fair value of RSUs vested during the three months ended March 28, 2020 was $1.0 million.
Performance Restricted Stock Units
We may grant Performance RSUs ("PRSUs") to certain executives, which vest based upon us achieving certain market performance criteria. There were no PRSUs granted during the three months ended March 28, 2020. PRSUs are included as part of the RSU activity above.
Stock Options
Stock option activity under our equity incentive plan was as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Options Outstanding | | Weighted Average Exercise Price | | Weighted Average Remaining Contractual Life in Years | | Aggregate Intrinsic Value |
Outstanding at December 28, 2019 | | 361,769 | | | $ | 8.35 | | | | | |
| | | | | | | | |
Options exercised | | (55,769) | | | 8.01 | | | | | |
| | | | | | | | |
Outstanding at March 28, 2020 | | 306,000 | | | $ | 8.41 | | | 1.88 | | $ | 3,607,620 | |
Vested and expected to vest at March 28, 2020 | | 306,000 | | | $ | 8.41 | | | 1.88 | | $ | 3,607,620 | |
Exercisable at March 28, 2020 | | 306,000 | | | $ | 8.41 | | | 1.88 | | $ | 3,607,620 | |
Employee Stock Purchase Plan
Information related to activity under our Employee Stock Purchase Plan ("ESPP") was as follows:
| | | | | | | | |
| | Three Months Ended |
| | March 28, 2020 |
Shares issued | | 311,591 | |
Weighted average per share purchase price | | $ | 13.05 | |
Weighted average per share discount from the fair value of our common stock on the date of issuance | | $ | 12.26 | |
Stock-Based Compensation
Stock-based compensation was included in our Condensed Consolidated Statements of Income as follows (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Cost of revenues | $ | 937 | | | $ | 950 | | | | | |
Research and development | 1,439 | | | 1,519 | | | | | |
Selling, general and administrative | 3,247 | | | 2,826 | | | | | |
Total stock-based compensation | $ | 5,623 | | | $ | 5,295 | | | | | |
Unrecognized Compensation Costs
At March 28, 2020, the unrecognized stock-based compensation was as follows (dollars in thousands):
| | | | | | | | | | | |
| Unrecognized Expense | | Average Expected Recognition Period in Years |
| | | |
Restricted stock units | $ | 20,158 | | | 1.79 |
Performance restricted stock units | 5,544 | | | 1.79 |
Employee stock purchase plan | 662 | | | 0.85 |
Total unrecognized stock-based compensation expense | $ | 26,364 | | | 1.77 |
Note 10 — Net Income per Share
The following table reconciles the shares used in calculating basic net income per share and diluted net income per share (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weighted-average shares used in computing basic net income per share | 76,005 | | | 74,362 | | | | | |
Add potentially dilutive securities | 2,505 | | | 1,647 | | | | | |
Weighted-average shares used in computing diluted net income per share | 78,510 | | | 76,009 | | | | | |
| | | | | | | |
Securities not included as they would have been antidilutive | 9 | | | 38 | | | | | |
Note 11 — Commitments and Contingencies
Leases
See Note 12.
Contractual Obligations and Commitments
Our contractual obligations and commitments have not materially changed as of March 28, 2020 from those disclosed in our Annual Report on Form 10-K for the year ended December 28, 2019.
Legal Matters
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. As of March 28, 2020, and as of the filing of this Quarterly Report on Form 10-Q, we were not involved in any material legal proceedings.
Note 12 — Leases
We lease real estate space under non-cancelable operating lease agreements for commercial and industrial space, as well as for our corporate headquarters located in Livermore, California. Our leases have remaining terms of 1 to 15 years, and some leases include options to extend up to 20 years. We also have operating leases for automobiles with remaining lease terms of 1 to 4 years. We did not include any of our renewal options in our lease terms for calculating our lease liability as the renewal options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at this time. The weighted-average remaining lease term for our operating leases was 8 years as of March 28, 2020 and the weighted-average discount rate was 4.40%.
The components of lease expense were as follows (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Lease expense: | | | | | | | | | |
Operating lease expense | $ | 1,924 | | | $ | 1,745 | | | | | |
Short-term lease expense | 40 | | | 17 | | | | | |
Variable lease expense | 383 | | | 419 | | | | | |
| $ | 2,347 | | | $ | 2,181 | | | | | |
Future minimum payments under our non-cancelable operating leases were as follows as of March 28, 2020 (in thousands):
| | | | | | | | |
Fiscal Year | | Amount |
Remainder of 2020 | | $ | 5,692 | |
2021 | | 6,713 | |
2022 | | 5,546 | |
2023 | | 4,934 | |
2024 | | 4,769 | |
Thereafter | | 22,165 | |
Total minimum lease payments | | 49,819 | |
Less: interest | | (8,976) | |
Present value of net minimum lease payments | | 40,843 | |
Less: current portion | | (6,815) | |
Total long-term operating lease liabilities | | $ | 34,028 | |
Note 13 — Revenue
Transaction price allocated to the remaining performance obligations: On March 28, 2020, we had $4.0 million of remaining performance obligations, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. We expect to recognize approximately 70% of our remaining performance obligations as revenue in the remainder of fiscal 2020, approximately 19% in fiscal 2021, and approximately 11% in fiscal 2022 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.
Contract balances: The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable is recorded at the invoiced amount, net of an allowance for doubtful accounts. A receivable is recognized in the period we deliver goods or provide services or when our right to consideration is unconditional. A contract asset is recorded when we have performed under the contract but our right to consideration is conditional on something other than the passage of time. Contract assets as of March 28, 2020 and December 28, 2019 were $2.6 million and $0.9 million, respectively, and are reported on the Condensed Consolidated Balance Sheets as a component of Prepaid expenses and other current assets.
Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the Condensed Consolidated Balance Sheets at the end of each reporting period as a component of Deferred revenue and Other liabilities. Contract liabilities as of March 28, 2020 and December 28, 2019 were $10.7 million and $10.8 million, respectively. During the three months ended March 28, 2020, we recognized $5.8 million of revenue, that was included in contract liabilities as of December 28, 2019.
Costs to obtain a contract: We generally expense sales commissions when incurred as a component of Selling, general and administrative expense, as the amortization period is typically less than one year.
Revenue by Category: Refer to Note 14 of Notes to Condensed Consolidated Financial Statements for further details.
Note 14 — Operating Segments and Enterprise-Wide Information
Our chief operating decision maker ("CODM") is our Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire company. We operate in two reportable segments consisting of the Probe Cards segment and the Systems segment. The following table summarizes the operating results by reportable segment (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | | | | | | | | | |
| March 28, 2020 | | | | | | | | March 30, 2019 | | | | | | |
| Probe Cards | | Systems | | Corporate and Other | | Total | | Probe Cards | | Systems | | Corporate and Other | | Total |
Revenues | $ | 134,715 | | | $ | 26,038 | | | $ | — | | | $ | 160,753 | | | $ | 108,103 | | | $ | 24,110 | | | $ | — | | | $ | 132,213 | |
Gross profit | $ | 60,743 | | | $ | 13,334 | | | $ | (6,687) | | | $ | 67,390 | | | $ | 45,294 | | | $ | 13,016 | | | $ | (5,789) | | | $ | 52,521 | |
Gross margin | 45.1 | % | | 51.2 | % | | — | % | | 41.9 | % | | 41.9 | % | | 54.0 | % | | — | % | | 39.7 | % |
| | | | | | | | | | | | | | | |
Operating results provide useful information to our management for assessment of our performance and results of operations. Certain components of our operating results are utilized to determine executive compensation along with other measures.
Corporate and Other includes unallocated expenses relating to amortization of intangible assets, share-based compensation, and restructuring charges, net, which are not used in evaluating the results of, or in allocating resources to, our reportable segments.
Certain revenue category information by reportable segment was as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | | | | | |
| March 28, 2020 | | | | | | March 30, 2019 | | | | |
| Probe Cards | | Systems | | Total | | Probe Cards | | Systems | | Total |
Market: | | | | | | | | | | | |
Foundry & Logic | $ | 105,745 | | | $ | — | | | $ | 105,745 | | | $ | 71,580 | | | $ | — | | | $ | 71,580 | |
DRAM | 24,696 | | | — | | | 24,696 | | | 28,886 | | | — | | | 28,886 | |
Flash | 4,274 | | | — | | | 4,274 | | | 7,637 | | | — | | | 7,637 | |
Systems | — | | | 26,038 | | | 26,038 | | | — | | | 24,110 | | | 24,110 | |
Total | $ | 134,715 | | | $ | 26,038 | | | $ | 160,753 | | | $ | 108,103 | | | $ | 24,110 | | | $ | 132,213 | |
Timing of revenue recognition: | | | | | | | | | | | |
Products transferred at a point in time | $ | 134,069 | | | $ | 24,858 | | | $ | 158,927 | | | $ | 107,491 | | | $ | 23,142 | | | $ | 130,633 | |
Services transferred over time | 646 | | | 1,180 | | | 1,826 | | | 612 | | | 968 | | | 1,580 | |
Total | $ | 134,715 | | | $ | 26,038 | | | $ | 160,753 | | | $ | 108,103 | | | $ | 24,110 | | | $ | 132,213 | |
Geographical region: | | | | | | | | | | | |
China | $ | 37,280 | | | $ | 6,362 | | | $ | 43,642 | | | $ | 18,151 | | | $ | 3,692 | | | $ | 21,843 | |
United States | 25,611 | | | 6,305 | | | 31,916 | | | 27,655 | | | 6,608 | | | 34,263 | |
Taiwan | 30,439 | | | 1,341 | | | 31,780 | | | 21,257 | | | 1,130 | | | 22,387 | |
Europe | 16,210 | | | 4,833 | | | 21,043 | | | 5,373 | | | 4,120 | | | 9,493 | |
South Korea | 13,692 | | | 396 | | | 14,088 | | | 25,018 | | | 1,705 | | | 26,723 | |
Japan | 5,535 | | | 2,835 | | | 8,370 | | | 5,300 | | | 5,132 | | | 10,432 | |
Asia-Pacific1 | 4,455 | | | 3,408 | | | 7,863 | | | 2,790 | | | 473 | | | 3,263 | |
Rest of the world | 1,493 | | | 558 | | | 2,051 | | | 2,559 | | | 1,250 | | | 3,809 | |
Total | $ | 134,715 | | | $ | 26,038 | | | $ | 160,753 | | | $ | 108,103 | | | $ | 24,110 | | | $ | 132,213 | |
1 Asia-Pacific includes all countries in the region except China, Japan, South Korea, and Taiwan, which are disclosed separately.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Statement Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, which are subject to risks and uncertainties. The forward-looking statements include statements concerning, among other things, our business strategy, financial and operating results, gross margins, liquidity and capital expenditure requirements and impact of accounting standards. In some cases, you can identify these statements by forward-looking words, such as "may," "might," "will," "could," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "intend" and "continue," the negative or plural of these words and other comparable terminology.
The forward-looking statements are only predictions based on our current expectations and our projections about future events. All forward-looking statements included in this Quarterly Report on Form 10-Q are based upon information available to us as of the filing date of this Quarterly Report on Form 10-Q. You should not place undue reliance on these forward-looking statements. We have no obligation to update any of these statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements, including risks related to general market trends, uncertainties related to COVID-19 and the impact of our responses to it, the interpretation and impacts of changes in export controls and other trade barriers, our ability to execute our business strategy and other risks discussed in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 28, 2019 and in this Quarterly Report on Form 10-Q. You should carefully consider the numerous risks and uncertainties described under these sections.
The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the accompanying notes contained in this Quarterly Report on Form 10-Q. Unless expressly stated or the context otherwise requires, the terms “we,” “our,” “us” and “FormFactor” refer to FormFactor, Inc. and its subsidiaries.
Overview
FormFactor, Inc., headquartered in Livermore, California, is a leading provider of test and measurement solutions. We provide a broad range of high-performance probe cards, analytical probes, probe stations, metrology systems, and thermal sub-systems to both semiconductor companies and scientific institutions. Our products provide electrical and optical information from a variety of semiconductor and electro-optical devices and integrated circuits from research, through development to production. Customers use our products and services to lower production costs, improve yields, and enable development of their complex next-generation products.
We operate in two reportable segments consisting of the Probe Cards segment and the Systems segment. Sales of our probe cards and analytical probes are included in the Probe Cards segment, while sales of our probe stations, metrology systems and thermal sub-systems are included in the Systems segment.
We generated net income of $15.9 million in the first three months of fiscal 2020 as compared to $5.5 million in the first three months of fiscal 2019. The increase in net income was primarily due to higher revenues, partially offset by higher operating expenses, both generated by higher operating levels.
Impact of COVID-19
An outbreak of an illness caused by a novel coronavirus in 2019 (“COVID-19”) has resulted in millions of infections and well over one hundred thousand deaths worldwide as of the date of filing this Quarterly Report. COVID-19 continues to spread in many of the regions that we, our customers and our suppliers operate. The COVID-19 pandemic has resulted in significant governmental measures being implemented to control the spread of the virus, including the imposition of stay-at-home and other orders in locations where we have manufacturing and other activities. We experienced a significant disruption to our operations as a result of the COVID-19 pandemic during the last two weeks of our first fiscal quarter of 2020 which continues, although currently to a lessening extent.
We believe that we operate in a critical infrastructure industry, as defined by the U.S. Department of Homeland Security. This reduces the current and anticipated impacts of the COVID-19 pandemic on our major customers and suppliers, and upon our operations, as compared to companies that are not part of the critical infrastructure. After a temporary suspension of manufacturing to implement safety measures in our California and Oregon locations, consistent with federal guidelines and state and local orders, we recommenced manufacturing. We currently continue to operate in all of our manufacturing sites
subject to certain safety and related constraints. Our other operations are similarly continuing with substantial work-from-home activities.
If the provisions of governmental health orders or other safety requirements continue for an extended period of time, or if we have occurrences of COVID-19 in any of our facilities, we may experience further disruptions or delays in manufacturing, product design, product development, customer support, manufacturing and sales, and an overall loss of productivity and efficiency. The progression of the COVID-19 pandemic could also negatively impact our business or results of operations through new restrictions at our operating locations or at those of our customers or suppliers.
Even with our continued operations, COVID-19 has had, and may have further, negative impacts on our supply chain, workforce and customers. As the COVID-19 pandemic is a widespread public health crisis, it is also adversely affecting major economies and financial markets world-wide. A resulting economic downturn can be expected to eventually negatively affect the demand for our products, and contribute to volatile demand and supply conditions affecting the markets for our products.
Governments in several countries where we operate, including the United States, have enacted stabilization and stimulus measures in an effort to counteract some of the impacts of COVID-19. We may benefit from some of these measures, although we do not believe those benefits will have a material effect upon our financial results or financial condition.
While to date the disruptions in our operations, supply chain and customer demand as a result of the COVID-19 pandemic have been somewhat limited, we believe that the COVID-19 pandemic represents a sustained threat that may eventually give rise to a variety of more significant adverse impacts on our business and financial results. We consider this as a near or longer term trend, although we cannot identify or quantify the specific impacts given current levels of uncertainty and the broad variety of effects that may arise from a pandemic of this magnitude. For a further description of the uncertainties and business risks associated with the COVID-19 pandemic, see the section entitled “Risk Factors” in this Quarterly Report.
Critical Accounting Policies and the Use of Estimates
Management’s Discussion and Analysis and Note 2 to the Consolidated Financial Statements in our 2019 Annual Report on Form 10-K describe the significant accounting estimates and critical accounting policies used in preparation of the Consolidated Financial Statements. Actual results in these areas could differ from management’s estimates. During the three months ended March 28, 2020, there were no significant changes in our critical accounting policies or estimates from those reported in our Annual Report on Form 10-K for the year ended December 28, 2019, which was filed with the Securities and Exchange Commission on February 21, 2020.
Results of Operations
The following table sets forth our operating results as a percentage of revenues for the periods indicated:
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Revenues | 100.0 | % | | 100.0 | % | | | | |
Cost of revenues | 58.1 | | | 60.3 | | | | | |
Gross profit | 41.9 | | | 39.7 | | | | | |
Operating expenses: | | | | | | | | | |
Research and development | 13.2 | | | 14.9 | | | | | |
Selling, general and administrative | 17.2 | | | 19.0 | | | | | |
| | | | | | | |
| | | | | | | |
Total operating expenses | 30.4 | | | 33.9 | | | | | |
Operating income | 11.5 | | | 5.8 | | | | | |
Interest income | 0.4 | | | 0.4 | | | | | |
Interest expense | (0.2) | | | (0.5) | | | | | |
Other expense, net | (0.1) | | | (0.1) | | | | | |
Income before income taxes | 11.6 | | | 5.6 | | | | | |
Provision for income taxes | 1.8 | | | 1.5 | | | | | |
Net income | 9.8 | % | | 4.1 | % | | | | |
Revenues by Segment and Market
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
| (In thousands) | | | | | | |
Probe Cards | $ | 134,715 | | | $ | 108,103 | | | | | |
Systems | 26,038 | | | 24,110 | | | | | |
| $ | 160,753 | | | $ | 132,213 | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | | | | | |
| March 28, 2020 | | % of Revenues | | March 30, 2019 | | % of Revenues | | $ Change | | % Change |
| (Dollars in thousands) | | | | | | | | | | |
Probe Cards Markets: | | | | | | | | | | | |
Foundry & Logic | $ | 105,745 | | | 65.8 | % | | $ | 71,580 | | | 54.1 | % | | $ | 34,165 | | | 47.7 | % |
DRAM | 24,696 | | | 15.4 | | | 28,886 | | | 21.9 | | | (4,190) | | | (14.5) | |
Flash | 4,274 | | | 2.7 | | | 7,637 | | | 5.8 | | | (3,363) | | | (44.0) | |
Systems Market: | | | | | | | | | | | | | | | | | |
Systems | 26,038 | | | 16.1 | | | 24,110 | | | 18.2 | | | 1,928 | | | 8.0 | |
Total revenues | $ | 160,753 | | | 100.0 | % | | $ | 132,213 | | | 100.0 | % | | $ | 28,540 | | | 21.6 | % |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
The increase in Foundry & Logic product revenue for the three months ended March 28, 2020, compared to the three months ended March 30, 2019, was driven principally by increased unit sales to large semiconductor foundries and integrated device manufacturers, as they increased manufacturing of new chip designs on leading-edge nodes.
The decrease in DRAM product revenue for the three months ended March 28, 2020, compared to the three months ended March 30, 2019, was driven by decreased unit sales as a result of decreased customer demand.
The decrease in Flash product revenue for the three months ended March 28, 2020, compared to the three months ended March 30, 2019, was driven by decreased unit sales as a result of decreased customer demand, as our revenue in this market continues to be highly variable.
The increase in Systems product revenue for the three months ended March 28, 2020, compared to the three months ended March 30, 2019, was driven by increased sales of probe stations, which includes an increase in revenue from 300mm stations, partially offset by lower revenue from thermal sub-systems and 200mm stations.
Due to COVID-19, there were various impacts across our segments due to governmental mandates of social distancing. This resulted in a temporary factory shut down for almost two weeks in certain locations, limiting our manufacturing capacity. These shutdowns negatively affected revenue, especially in our Probes segment.
Revenues by Geographic Region
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | | | | | | | | | |
| March 28, 2020 | | % of Revenue | | March 30, 2019 | | % of Revenue | | | | | | | | |
| (Dollars in thousands) | | | | | | | | | | | | | | |
China | $ | 43,642 | | | 27.1 | % | | $ | 21,843 | | | 16.5 | % | | | | | | | | |
United States | 31,916 | | | 19.9 | % | | 34,263 | | | 25.9 | % | | | | | | | | |
Taiwan | 31,780 | | | 19.8 | % | | 22,387 | | | 16.9 | % | | | | | | | | |
Europe | 21,043 | | | 13.1 | % | | 9,493 | | | 7.2 | % | | | | | | | | |
South Korea | 14,088 | | | 8.8 | % | | 26,723 | | | 20.2 | % | | | | | | | | |
Japan | 8,370 | | | 5.2 | % | | 10,432 | | | 7.9 | % | | | | | | | | |
Asia-Pacific1 | 7,863 | | | 4.9 | % | | 3,263 | | | 2.5 | % | | | | | | | | |
Rest of the world | 2,051 | | | 1.2 | % | | 3,809 | | | 2.9 | % | | | | | | | | |
Total revenues | $ | 160,753 | | | 100.0 | % | | $ | 132,213 | | | 100.0 | % | | | | | | | | |
1 Asia-Pacific includes all countries in the region except China, Japan, South Korea and Taiwan, which are disclosed separately.
Geographic revenue information is based on the location to which we ship the product. For example, if a certain South Korean customer purchases through their U.S. subsidiary and requests the products to be shipped to an address in South Korea, this sale will be reflected in the revenue for South Korea rather than the U.S.
Changes in revenue by geographic region for the three months ended March 28, 2020, compared to the three months ended March 30, 2019, was primarily attributable to changes in customer demand, shifts in customer regional manufacturing strategies, and product sales mix.
Cost of Revenues and Gross Margins
Cost of revenues consists primarily of manufacturing materials, compensation and benefits, shipping and handling costs, manufacturing-related overhead and amortization of certain intangible assets. Our manufacturing operations rely on a limited number of suppliers to provide key components and materials for our products, some of which are a sole source. We order materials and supplies based on backlog and forecasted customer orders. Tooling and setup costs related to changing manufacturing lots at our suppliers are also included in the cost of revenues. We expense all warranty costs, inventory provisions and amortization of certain intangible assets as cost of revenues.
Our gross profit and gross margin were as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | $ Change | | % Change |
Gross profit | $ | 67,390 | | | $ | 52,521 | | | $ | 14,869 | | | 28.3 | % |
Gross margin | 41.9 | % | | 39.7 | % | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Our gross profit and gross margin by segment were as follows (dollars in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | | | | | | | | | |
| March 28, 2020 | | | | | | | | March 30, 2019 | | | | | | |
| Probe Cards | | Systems | | Corporate and Other | | Total | | Probe Cards | | Systems | | Corporate and Other | | Total |
Gross profit | $ | 60,743 | | | $ | 13,334 | | | $ | (6,687) | | | $ | 67,390 | | | $ | 45,294 | | | $ | 13,016 | | | $ | (5,789) | | | $ | 52,521 | |
Gross margin | 45.1 | % | | 51.2 | % | | — | % | | 41.9 | % | | 41.9 | % | | 54.0 | % | | — | % | | 39.7 | % |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
Probe Cards
For the three months ended March 28, 2020, gross profit and gross margins increased compared to the three months ended March 30, 2019, primarily due to increased sales and higher factory utilization.
Systems
For the three months ended March 28, 2020, gross profit increased while gross margin decreased compared to the three months ended March 30, 2019, primarily as a result of product mix and additional contribution from our acquisition of FRT GmbH.
Corporate and Other
Corporate and Other includes unallocated expenses relating to amortization of intangible assets, share-based compensation, and restructuring charges, net, which are not used in evaluating the results of, or in allocating resources to, our reportable segments.
Overall
Gross profit and gross margin fluctuate with revenue levels, product mix, selling prices, factory loading and material costs. For the three months ended March 28, 2020, compared to the three months ended March 30, 2019, gross profit and gross margins have improved, primarily on higher sales.
Cost of revenues included stock-based compensation expense as follows (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Stock-based compensation | $ | 937 | | | $ | 950 | | | | | |
Future gross margins may be adversely impacted by lower revenues, unfavorable product mix and lower factory utilization. Our gross margins may also be adversely affected if we are required to record additional inventory write-downs for estimated average selling prices that are below cost or because of a decrease in demand.
Research and Development
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | $ Change | | % Change |
| (Dollars in thousands) | | | | | | |
Research and development | $ | 21,267 | | | $ | 19,723 | | | $ | 1,544 | | | 7.8 | % |
% of revenues | 13.2 | % | | 14.9 | % | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
The increase in research and development expenses in the three months ended March 28, 2020 when compared to the corresponding period in the prior year was primarily driven by increased headcount combined with higher variable compensation, partially offset by a decrease in project material costs.
A detail of the changes is as follows (in thousands):
| | | | | | | |
| Three Months Ended March 28, 2020 compared to Three Months Ended March 30, 2019 | | |
Employee compensation costs | $ | 1,649 | | | |
Depreciation | 88 | | | |
Stock-based compensation | (80) | | | |
Project material costs | (65) | | | |
Other general operations | (48) | | | |
| $ | 1,544 | | | |
Research and development included stock-based compensation expense as follows (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Stock-based compensation | $ | 1,439 | | | $ | 1,519 | | | | | |
Selling, General and Administrative
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | $ Change | | % Change |
| (Dollars in thousands) | | | | | | |
Selling, general and administrative | $ | 27,693 | | | $ | 25,184 | | | $ | 2,509 | | | 10.0 | % |
% of revenues | 17.2 | % | | 19.0 | % | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
The increase in selling, general and administrative in the three months ended March 28, 2020 when compared to the corresponding period in the prior year was primarily due to increased headcount combined with higher variable compensation, higher stock-based compensation related to the timing of annual grants, and higher costs from acquisition of FRT GmbH, offset partially by a decrease in the amortization of intangible assets.
A detail of the changes is as follows (in thousands):
| | | | | | | |
| Three Months Ended March 28, 2020 compared to Three Months Ended March 30, 2019 | | |
Employee compensation | 1,942 | | | |
Amortization of intangibles | (858) | | | |
Consulting fees | 566 | | | |
Stock-based compensation | 421 | | | |
General operating expenses | 438 | | | |
| $ | 2,509 | | | |
Selling, general and administrative included stock-based compensation expense as follows (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
Stock-based compensation | $ | 3,247 | | | $ | 2,826 | | | | | |
Interest Income and Interest Expense
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
| (Dollars in thousands) | | | | | | |
Interest Income | $ | 685 | | | $ | 580 | | | | | |
Weighted average balance of cash and investments | | $ | 210,791 | | | $ | 151,451 | | | | | |
Weighted average yield on cash and investments | | 1.68 | % | | 2.03 | % | | | | |
| | | | | | | |
Interest Expense | $ | 318 | | | $ | 595 | | | | | |
Average debt outstanding | $ | 42,854 | | | $ | 64,835 | | | | | |
Weighted average interest rate on debt | 2.50 | % | | 4.51 | % | | | | |
Interest income is earned on our cash, cash equivalents, restricted cash and marketable securities. The increase in interest income for the three months ended March 28, 2020 compared with the corresponding period of the prior year was attributable to higher invested balances and sustained investment yields, related in part to longer duration investments.
Interest expense primarily includes interest on our term loans, partially offset by income from our interest-rate swap derivative contracts, as well as term loan issuance costs amortization charges. The decrease in interest expense for the three months ended March 28, 2020 compared to the same period of the prior year was primarily due to lower outstanding debt balances related to the acquisition of Cascade Microtech in fiscal 2016 as a result of principal payments made, partially offset by additional interest expense related to the term loan originated to finance the acquisition of FRT GmbH in the fourth quarter of 2019.
Other Expense, Net
Other expense, net, primarily includes the effects of foreign currency impact and various other gains and losses.
Provision for Income Taxes
| | | | | | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 28, 2020 | | March 30, 2019 | | | | |
| (In thousands, except percentages) | | | | | | |
Provision for income taxes | $ | 2,816 | | | $ | 2,032 | | | | | |
Effective tax rate | 15.1 | % | | 27.0 | % | | | | |
Provision for income taxes reflects the tax provision on our operations in foreign and U.S. jurisdictions, offset by tax benefits from tax credits and the foreign-derived intangible income ("FDII") deduction. We expect the FDII deduction and corresponding benefit to be available after utilizing our previous net operating loss carryforwards, resulting in a decrease in our effective tax rate for the three months ended March 28, 2020, compared to the three months ended March 30, 2019. Our effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to U.S. federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.
Liquidity and Capital Resources
Capital Resources
Our working capital was $308.8 million at March 28, 2020, compared to $282.5 million at December 28, 2019.
Cash and cash equivalents primarily consist of deposits held at banks and money market funds. Marketable securities primarily consist of U.S. treasuries, U.S. agency securities and corporate bonds. We typically invest in highly-rated securities with low probabilities of default. Our investment policy requires investments to be rated single A or better, and limits the types of acceptable investments, issuer concentration and duration of the investment.
Our cash, cash equivalents and marketable securities totaled approximately $239.4 million at March 28, 2020, compared to $220.9 million at December 28, 2019. We believe that we will be able to satisfy our working capital requirements and scheduled term loan repayments for at least the next twelve months with the liquidity provided by our existing cash, cash
equivalents, marketable securities and cash provided by operations. To the extent necessary, we may consider entering into short and long-term debt obligations, raising cash through a stock issuance, or obtaining new financing facilities, which may not be available on terms favorable to us. Our future capital requirements may vary materially from those now planned.
The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition. As a result of the current and uncertain future impact of COVID-19, we have taken actions to preserve and improve our liquidity primarily by limiting our exposures to volatile markets and investments, as well as actively working to minimize counterparty risk.
If we are unsuccessful in maintaining or growing our revenues, maintaining or reducing our cost structure (in response to a potential reduction in demand due to an industry downturn, COVID-19, or other event), or increasing our available cash through debt or equity financings, our cash, cash equivalents and marketable securities may decline in fiscal 2020.
We utilize a variety of tax planning and financing strategies to manage our worldwide cash and deploy funds to locations where needed. As part of these strategies, we indefinitely reinvest a portion of our foreign earnings. Should we require additional capital in the United States, we may elect to repatriate indefinitely-reinvested foreign funds or raise capital in the United States.
Cash Flows
The following table sets forth our net cash flows from operating, investing and financing activities:
| | | | | | | | | | | |
| Three Months Ended | | |
| March 28, 2020 | | March 30, 2019 |
| (In thousands) | | |
Net cash provided by operating activities | $ | 39,339 | | | $ | 20,638 | |
Net cash used in investing activities | (5,442) | | | (9,332) | |
Net cash used in financing activities | $ | (9,071) | | | $ | (3,932) | |
Operating Activities
Net cash provided by operating activities for the three months ended March 28, 2020 was primarily attributable to net income of $15.9 million and $22.7 million of net non-cash expenses, offset by changes in operating assets and liabilities, as explained below.
Accounts receivable, net, decreased $7.8 million to $90.1 million at March 28, 2020, compared to $97.9 million at December 28, 2019, as a result of changes in customer sales mix, timing of customer shipments and timing of customer payments.
Inventories, net, decreased $4.3 million to $79.0 million at March 28, 2020, compared to $83.3 million at December 28, 2019, as a result of shipping prior quarter backlog, lower inventory production, and less inventory receipts at the end of the quarter primarily due to reduced operating levels under COVID-19 restrictions, as previously described.
Accrued liabilities decreased $7.3 million to $29.2 million at March 28, 2020, compared to $36.4 million at December 28, 2019, as a result of timing of payments including employee performance-based compensation and indirect taxes.
Investing Activities
Net cash used in investing activities for the three months ended March 28, 2020 was primarily related to $12.1 million of cash used in the acquisition of property, plant and equipment partially offset by $6.6 million of net proceeds from sales of marketable securities.
Financing Activities
Net cash used in financing activities for the three months ended March 28, 2020 primarily related to $13.2 million of principal payments made towards the repayment of our term loans and $0.4 million related to tax withholding associated with the net share settlements of our equity awards, partially offset by $4.5 million of proceeds received from issuances of common stock under our employee stock purchase plan and stock option plans.
Debt
CMI Term Loan
On June 24, 2016, we entered into a Credit Agreement (the “Credit Agreement”) with HSBC Bank USA, National Association ("HSBC"), as administrative agent, co-lead arranger, sole bookrunner and syndication agent, other lenders that may from time-to-time be a party to the Credit Agreement, and certain guarantors. Pursuant to the Credit Agreement, the lenders have provided us with a senior secured term loan facility of $150 million (the “CMI Term Loan”). The proceeds of the CMI Term Loan were used to finance a portion of the purchase price paid in connection with the Cascade Microtech acquisition in fiscal 2016 and to pay related bank fees and expenses.
The CMI Term Loan bears interest at a rate equal to, at our option, (i) the applicable London Interbank Offered Rate ("LIBOR") rate plus 2.00% per annum or (ii) Base Rate (as defined in the Credit Agreement) plus 1.00% per annum. We have currently elected to pay interest at 2.00% over the one-month LIBOR rate. Interest payments are payable in monthly installments over a five-year period. The interest rate at March 28, 2020 was 3.61%.
The principal payments on the CMI Term Loan are paid in equal quarterly installments that began June 30, 2016, in an annual amount equal to 5% for year one, 10% for year two, 20% for year three, 30% for year four and 35% for year five. The planned final payment on the CMI Term Loan is scheduled for the third quarter of fiscal 2020.
On July 25, 2016, we entered into an interest rate swap agreement with HSBC and other lenders to hedge the interest payments on the CMI Term Loan for the notional amount of $95.6 million. As future levels of LIBOR over the life of the loan are uncertain, we entered into these interest-rate swap agreements to hedge the exposure in interest rate risks associated with movement in LIBOR rates. By entering into the agreements, we convert a floating rate interest at one-month LIBOR plus 2% into a fixed rate interest at 2.939%. The interest rate swap agreement ended as of March 28, 2020.
The obligations under the Term Loan are guaranteed by substantially all of our assets and the assets of our domestic subsidiaries, subject to certain customary exceptions.
The Credit Agreement contains negative covenants customary for financing of this type, as well as certain financial maintenance covenants. As of March 28, 2020, the balance outstanding pursuant to the CMI Term Loan was $23.7 million and we were in compliance with all covenants under the Credit Agreement.
FRT Term Loan
On October 25, 2019, we entered into a $23.4 million three-year credit facility loan agreement (the "FRT Term Loan") with HSBC Trinkaus & Burkhardt AG, Germany, to fund the acquisition of FRT GmbH, which we acquired on October 9, 2019. See Note 4 for further details of the acquisition.
The FRT Term Loan bears interest at a rate equal to the Euro Interbank Offered Rate ("EURIBOR") plus 1.75 % per annum and will be repaid in quarterly installments of approximately $1.9 million plus interest beginning January 25, 2020.
The obligations under the FRT Term Loan are fully and unconditionally guaranteed by FormFactor, Inc. The Credit Facility contains negative covenants customary for financing of this type, including covenants that place limitations on the incurrence of additional indebtedness, the creation of liens, the payment of dividends; dispositions; fundamental changes, including mergers and acquisitions; loans and investments; sale leasebacks; negative pledges; transactions with affiliates; changes in fiscal year; sanctions and anti-bribery laws and regulations, and modifications to charter documents in a manner materially adverse to the Lenders. The FRT Term Loan also contains affirmative covenants and representations and warranties customary for financing of this type. As of March 28, 2020, the balance outstanding pursuant to the FRT term loan was $21.4 million and we were in compliance with all covenants.
Contractual Obligations and Commitments
Other than our operating lease commitments as disclosed in Note 12 of Notes to Condensed Consolidated Financial Statements, our contractual obligations and commitments have not materially changed as of March 28, 2020 from those disclosed in our Annual Report on Form 10-K for the year ended December 28, 2019.
Off-Balance Sheet Arrangements
Historically, we have not participated in transactions that have generated relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been
established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of March 28, 2020, we were not involved in any such off-balance sheet arrangements.
Recent Accounting Pronouncements
See Note 1 of Notes to Condensed Consolidated Financial Statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to Item 7A “Quantitative and Qualitative Disclosures about Market Risk” contained in Part II of our Annual Report on Form 10-K for the fiscal year ended December 28, 2019. Our exposure to market risk has not changed materially since December 28, 2019.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Based on our management’s evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”)) are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on the Effectiveness of Controls
Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems’ objectives are being met. Further, the design of any control systems must reflect the fact that there are resource constraints, and the benefits of all controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based, in part, on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
CEO and CFO Certifications
We have attached as exhibits to this Quarterly Report on Form 10-Q the certifications of our Chief Executive Officer and Chief Financial Officer, which are required in accordance with the Exchange Act. We recommend that this Item 4 be read in conjunction with the certifications for a more complete understanding of the subject matter presented.
PART II - OTHER INFORMATION
Item 1A. Risk Factors
There have been no material changes during the three months ended March 28, 2020 to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 28, 2019 apart from the risk factor described below. If any of the identified risks actually occur, our business, financial condition and results of operations could suffer. The trading price of our common stock could decline and you may lose all or part of your investment in our common stock. The risks and uncertainties described
in our Annual Report on Form 10-K for the year ended December 28, 2019 are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business operations.
The COVID-19 pandemic has impacted, and is expected to continue to negatively impact, our operations, and those of our important suppliers, business partners and customers.
We are exposed to risks associated with public health crises and outbreaks of contagious diseases, such as the current outbreak of a novel strain of coronavirus ("COVID-19"). To date, COVID-19 has had, and may continue to have, an adverse impact on our operations, our supply chains and our expenses, including as a result of precautionary measures that we take in response to COVID-19.
The COVID-19 pandemic has created significant volatility, uncertainty and economic disruption, which has adversely affected, and will continue to adversely affect, our business operations and may materially and adversely affect our results of operations, cash flows and financial position.
As a result of the COVID-19 pandemic, we have experienced significant business disruptions, including temporary closures of our facilities, and the facilities of our suppliers and their supply chain partners, and restrictions on our ability to travel and service our products. For example, our corporate headquarters and many of our operations, including much of our manufacturing facilities, are located in California, which has instituted health orders applicable to our operations and employees in the region. In other regions where we operate globally, similar health orders have been issued which have had, and will continue to have, similar affects upon our business. This has significantly impacted our ability to design, produce, deliver and support our products for customers. These unprecedented measures to slow the spread of COVID-19 taken by local and regional governments have had, and will continue to have, a significant negative impact on our operations.
A significant amount of our management resources has been, and will continue to be, focused on mitigating the negative impacts of COVID-19 on our business. This has required, and will continue to require, a substantial investment of time and resources across our enterprise that has delayed, or may continue to delay other valuable activities, such as the development of new technologies, products or capabilities. In addition, many of our employees are working remotely for an extended period which can increase operational risk and cybersecurity risks. If we do not respond appropriately to the COVID-19 pandemic, or if customers do not perceive our response positively, we could suffer damage to our reputation, which could adversely affect our business.
The extent to which the COVID-19 pandemic impacts us will depend on numerous evolving factors and future developments that we are not able to predict, including: the severity of the virus; the duration of the outbreak; governmental, business and other actions (which could include restrictions on our operations); the ongoing requirements of social distancing and shelter-in-place orders; the impacts on our supply chain; the impact of the pandemic on economic activity; the extent and duration of the effect on business confidence and investments by our customers; the effects of changes to our operations that may continue indefinitely; the health of and the effect on our workforce and our ability to meet our staffing needs, particularly if members of our workforce are exposed or infected; any impairments in the value of our assets which could be recorded as a result of weaker economic conditions; and the potential impacts upon our internal controls including those over financial reporting that may result from changes in working environments and other circumstances. If the pandemic continues to create disruptions in the credit and financial markets, it could also adversely affect our ability to access capital on favorable terms to meet our business and strategic objectives. All of these circumstances are highly uncertain and cannot be predicted. In addition, the circumstances which give rise to new or existing infectious diseases becoming epidemics or pandemics with potentially similar impacts are expected to persist.
We obtain some of the components and materials used in our products from a sole source or a limited group of suppliers, and in some cases alternative sources are not readily available. Our dependence upon sole or limited source suppliers increases our exposure to the impacts of COVID-19 that might disrupt the operations of one or more of these suppliers, resulting in an inability to obtain an adequate supply of materials, late deliveries or poor component quality while we seek to identify and qualify alternative suppliers.
In addition, the COVID-19 pandemic has adversely affected, and may continue to adversely affect, regional and global economies and financial markets that can result in a period of economic slowdown or recession that could curtail or delay spending by businesses and consumers which may ultimately result in reductions in the demand for our products. As a result of the uncertain scope and duration of the COVID-19 pandemic and the uncertain timing of the regional and global recovery and economic normalization, we are unable to estimate the impacts on our operations and financial results. As a result, we may decide to limit or refrain from providing financial guidance in the manner we have done for recent reporting periods. All of these factors may negatively affect our stock price.
Increasingly restrictive export regulations and other trade barriers may materially harm our business.
Sales of our products to customers outside of the United States represent a significant part of our past and anticipated revenues, including sales involving exports from the United States to China. In 2019, sales in China represented 18% of our revenues, and China is an area of potential growth for our business. We have observed a continuing trend of increasing tariffs and trade controls affecting exports to China. For example, the U.S. Department of Commerce, Bureau of Industry and Security, has recently published amendments to the U.S. Export Administration Regulations to expand license requirements on exports to entities in China that may support military end uses. These rules are expected to, among other things, expand export license requirements on a broader set of items from the U.S., including many of our products. There is no assurance that we will obtain any such licenses on a timely basis or at all. There also remains considerable uncertainty regarding the interpretation and implementation of these rules. These and other regulatory changes could materially and negatively affect our future sales and operating results.
Item 6. Exhibits
The following exhibits are filed herewith and this list constitutes the exhibit index.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Exhibit | | | | Incorporated by Reference | | | | | | Filed |
Number | | Exhibit Description | | Form | | Date | | Number | | Herewith |
3.1 | | |
| | S-1 | | October 20, 2003 | | 3.01 | | |
3.2 | | |
| | 8-K | | July 22, 2016 | | 3.2 | | |
31.01 | | | | | | | | | | | X |
31.02 | | | | | | | | | | | X |
32.01 | | | | | | | | | | | * |
101.INS | | XBRL Instance Document | | | | | | | | X |
101.SCH | | XBRL Taxonomy Extension Schema Document | | | | | | | | X |
101.CAL | | XBRL Taxonomy Extension Calculation Linkbase Document | | | | | | | | X |
101.DEF | | XBRL Taxonomy Extension Definition Linkbase Document | | | | | | | | X |
101.LAB | | XBRL Taxonomy Extension Label Linkbase Document | | | | | | | | X |
101.PRE | | XBRL Taxonomy Extension Presentation Linkbase Document | | | | | | | | X |
| | | | | | | | | | |
______________________________________
* This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | | | | |
| | FormFactor, Inc. | |
| | | |
Date: | May 7, 2020 | By: | /s/ SHAI SHAHAR |
| | | |
| | | Shai Shahar |
| | | Chief Financial Officer |
| | | (Duly Authorized Officer, Principal Financial Officer, and Principal Accounting Officer) |